UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Increases Stock Position in Royalty Pharma PLC $RPRX

Key Points

• UBS Asset Management increased its stake in Royalty Pharma PLC by 8.6%, owning approximately 2.85 million shares valued at about $88.7 million as of its latest SEC filing.
• Royalty Pharma declared a quarterly dividend of $0.22 per share, with an annualized yield of 2.4% and a payout ratio of about 50.87%.
• Despite recent institutional buying trends, Royalty Pharma's stock has a market cap of $21.2 billion and is currently trading at $36.36, down 0.9%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 8.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,847,934 shares of the biopharmaceutical company's stock after acquiring an additional 226,048 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.49% of Royalty Pharma worth $88,656,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RPRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Royalty Pharma by 25.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 66,501 shares of the biopharmaceutical company's stock valued at $1,696,000 after acquiring an additional 13,376 shares during the last quarter. Nuveen Asset Management LLC lifted its position in Royalty Pharma by 0.9% in the fourth quarter. Nuveen Asset Management LLC now owns 944,601 shares of the biopharmaceutical company's stock valued at $24,097,000 after acquiring an additional 8,802 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its position in Royalty Pharma by 0.7% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock valued at $1,238,000 after acquiring an additional 349 shares during the last quarter. Man Group plc increased its stake in Royalty Pharma by 113.4% in the fourth quarter. Man Group plc now owns 815,427 shares of the biopharmaceutical company's stock valued at $20,802,000 after purchasing an additional 433,245 shares during the period. Finally, Quantinno Capital Management LP increased its stake in Royalty Pharma by 30.0% in the fourth quarter. Quantinno Capital Management LP now owns 73,380 shares of the biopharmaceutical company's stock valued at $1,872,000 after purchasing an additional 16,945 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Trading Down 0.9%

Shares of Royalty Pharma stock opened at $36.36 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $38.00. The company has a market capitalization of $21.20 billion, a P/E ratio of 21.02, a P/E/G ratio of 2.29 and a beta of 0.58. The business has a 50 day moving average price of $36.36 and a 200 day moving average price of $34.29.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The firm had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Sell-side analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. Royalty Pharma's dividend payout ratio is presently 50.87%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of recent research reports. Citigroup lifted their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a research note on Tuesday, July 22nd. Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Morgan Stanley lifted their price objective on shares of Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $48.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.